Group Structure
|
Chairman |
Paul Lorigan, Manchester |
|
Chairman-elect |
|
|
Secretary |
Mario Mandala, Perugia |
|
Treasurer |
Ghanem Ghanem, Brussels |
|
Past-chairman |
Alexander van Akkooi, Amsterdam |
The MG has eight committees concerned with the management of cutaneous and ocular melanoma, the development of new immunotherapy strategies, and basic sciences committees carrying out epidemiological, genetics, immunobiological and pathological studies on melanoma. Key is the extensive phase III trial program regarding treatments in virtually all stages of melanoma. This is supplemented with pathology studies focusing on molecular defects associated with melanoma progression and identification of new potential therapeutical targets, genetics studies focusing on constitutional factors associated with melanoma prognosis, and large epidemiological investigations, focusing on the relation of various aspects of UV irradiation and melanoma risk. The committee structure is adapted to the sharply increased activities of the group as follows:
|
Chair Adjuvant therapy Committee |
Alexander M. Eggermont, Paris |
|
Chair Epidemiology Committee |
Sara Gandini, Milan |
|
Chair Translational Research Committee |
Dirk Schadendorf, Essen |
|
Chair Early staging Committee |
Susana Puig, Barcelona |
|
Chair Ocular melanoma Committee |
Paul Nathan, Northwood |
|
Chair Pathology Committee |
Daniela Massi, Florence |
|
Chair Stage IV melanoma Committee |
Paul Lorigan, Manchester |
|
Chair Surgery Committee |
Alessandro Testori, Milan |
|
Early Career Investigators' Network representatives |
Sara Valpione, Manchester |
| Patient Representative | Violeta Astratinei, Stichting Melanoom NL |